Amy Hurwitz is a lead member of Boston Consulting Group's Corporate Finance & Strategy and Health Care practices. Her work focuses on strategy topics related to total shareholder return (TSR), growth and innovation, and transformations. She works with clients across industries, with a focus on medtech and biopharma, as well as health care more broadly.
Amy is a coauthor of BCG’s Most Innovative Companies Report, and her corporate innovation experience utilizes a multi-pronged approach to developing strategies, programs, and ecosystems. She also has considerable expertise in digital health, molecular diagnostics, pharmacology, life science tools, data analytics, deep tech, large scale transformation, and commercialization.
Before joining the firm, Amy worked as a research fellow in pharmacology at Baylor College of Medicine. She was a founder and board member of Enventure, a non-profit organization connecting life science entrepreneurs with educational and networking resources.
Synthetic biology is a difficult technology to master and especially tough to scale. Chemical and materials startups and their backers need to find the meeting place of technology capability, market need, and cost.
Companies have plenty of “will” but much less “way” when it comes to climate and sustainability innovation readiness.